214 related articles for article (PubMed ID: 23573238)
21. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
22. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
Grohskopf LA; Chillag KL; Gvetadze R; Liu AY; Thompson M; Mayer KH; Collins BM; Pathak SR; Oʼhara B; Ackers ML; Rose CE; Grant RM; Paxton LA; Buchbinder SP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):79-86. PubMed ID: 23466649
[TBL] [Abstract][Full Text] [Related]
24. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice.
Chateau ML; Denton PW; Swanson MD; McGowan I; Garcia JV
PLoS One; 2013; 8(3):e60024. PubMed ID: 23527295
[TBL] [Abstract][Full Text] [Related]
25. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
27. A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026).
Cranston RD; Brown E; Bauermeister J; Dunne EF; Hoesley C; Ho K; Johnson S; Lucas J; Dominguez-Islas C; Gundacker H; Peda M; Jacobson CE; Kramzer L; Singh D; Dezzutti CS; Kunjara Na Ayudhya RP; Brand RM; Wang L; Marzinke MA; Piper J; Devlin B; Nuttall J; McGowan I; Hendrix CW
AIDS Res Hum Retroviruses; 2022 Apr; 38(4):257-268. PubMed ID: 34498980
[TBL] [Abstract][Full Text] [Related]
28. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
[TBL] [Abstract][Full Text] [Related]
29. Mucosal effects of tenofovir 1% gel.
Hladik F; Burgener A; Ballweber L; Gottardo R; Vojtech L; Fourati S; Dai JY; Cameron MJ; Strobl J; Hughes SM; Hoesley C; Andrew P; Johnson S; Piper J; Friend DR; Ball TB; Cranston RD; Mayer KH; McElrath MJ; McGowan I
Elife; 2015 Feb; 4():. PubMed ID: 25647729
[TBL] [Abstract][Full Text] [Related]
30. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
31. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
[TBL] [Abstract][Full Text] [Related]
32. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
[TBL] [Abstract][Full Text] [Related]
33. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
[TBL] [Abstract][Full Text] [Related]
34. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
35. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
Anton PA; Saunders T; Elliott J; Khanukhova E; Dennis R; Adler A; Cortina G; Tanner K; Boscardin J; Cumberland WG; Zhou Y; Ventuneac A; Carballo-Diéguez A; Rabe L; McCormick T; Gabelnick H; Mauck C; McGowan I
PLoS One; 2011; 6(9):e23243. PubMed ID: 21969851
[TBL] [Abstract][Full Text] [Related]
36. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Clark MR; Friend DR
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
[TBL] [Abstract][Full Text] [Related]
38. Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.
Liu AY; Vittinghoff E; Chillag K; Mayer K; Thompson M; Grohskopf L; Colfax G; Pathak S; Gvetadze R; Oʼhara B; Collins B; Ackers M; Paxton L; Buchbinder SP
J Acquir Immune Defic Syndr; 2013 Sep; 64(1):87-94. PubMed ID: 23481668
[TBL] [Abstract][Full Text] [Related]
39. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
[TBL] [Abstract][Full Text] [Related]
40. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
